image credit: Freepik

Delphia starts up with $67M to make a new type of cancer drug

May 2, 2024


Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies. In the last decade alone, immunotherapies, targeted therapies, antibody-drug conjugates and radiopharmaceuticals have become standard treatment for a variety of tumors.

Yet none are silver bullets, leaving room for young companies testing out new ideas, like Delphia Therapeutics, which launched on Thursday with $67 million in funding.

“To get a different outcome for patients requires a different approach,” said Delphia co-founder and CEO Kevin Marks.

Read More on Biopharma Dive